An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Chimerix (CMRX) will host a conference call on May 1, 2024, to report Q1 2024 financial results and provide a business overview. The call will discuss the company's progress in developing medicines for deadly diseases.
Chimerix (CMRX) organizzerà una conferenza telefonica il 1° maggio 2024 per presentare i risultati finanziari del primo trimestre del 2024 e fornire una panoramica aziendale. Durante la chiamata verranno discussi i progressi dell'azienda nello sviluppo di farmaci per malattie mortali.
Chimerix (CMRX) realizará una llamada de conferencia el 1 de mayo de 2024 para informar sobre los resultados financieros del primer trimestre de 2024 y proporcionar una visión general del negocio. La llamada discutirá el progreso de la compañía en el desarrollo de medicamentos para enfermedades mortales.
Chimerix (CMRX)는 2024년 5월 1일에 2024년 제1분기 재무 결과를 보고하고 사업 개요를 제공하기 위해 컨퍼런스 콜을 개최할 예정입니다. 이 통화에서는 치명적인 질병을 치료하기 위한 의약품 개발에 대한 회사의 진전이 논의될 것입니다.
Chimerix (CMRX) organisera une conférence téléphonique le 1er mai 2024 pour présenter les résultats financiers du premier trimestre 2024 et fournir un aperçu des activités de l'entreprise. L'appel discutera des progrès de l'entreprise dans le développement de médicaments pour des maladies mortelles.
Chimerix (CMRX) wird am 1. Mai 2024 einen Telefonkonferenz abhalten, um die Finanzergebnisse des ersten Quartals 2024 zu berichten und einen Überblick über das Geschäft zu geben. In dem Anruf wird der Fortschritt des Unternehmens bei der Entwicklung von Medikamenten gegen tödliche Krankheiten besprochen.
Positive
None.
Negative
None.
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.
To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 1246220. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
CONTACT:
Will O’Connor Stern Investor Relations 212-362-1200 will@sternir.com
FAQ
When will Chimerix report its first-quarter 2024 financial results?
Chimerix will report its first-quarter 2024 financial results on May 1, 2024.
What time will the live conference call take place on May 1, 2024?
The live conference call will take place at 8:30 a.m. ET on May 1, 2024.
How can I access the live conference call?
To access the live conference call, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time and refer to conference ID 1246220.
Where can I find the live audio webcast of the call?
The live audio webcast will be available on the Investors’ section of Chimerix's website, www.chimerix.com.
Will there be an archived webcast available after the event?
Yes, an archived webcast will be available on the Chimerix website approximately two hours after the event.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
